Shares of Cambrex Corp. (NYSE:CBM) traded down 1.5% during mid-day trading on Friday . The company traded as low as $57.68 and last traded at $57.97, with a volume of 122,317 shares traded. The stock had previously closed at $58.85.

Separately, Zacks Investment Research lowered shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, June 29th.

The firm has a market cap of $1.84 billion and a P/E ratio of 29.50. The stock has a 50 day moving average price of $52.59 and a 200 day moving average price of $45.01.

Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings data on Friday, April 29th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.16. The company had revenue of $94.74 million for the quarter, compared to analyst estimates of $83.61 million. During the same period in the previous year, the business earned $0.29 EPS. The firm’s revenue was up 22.2% on a year-over-year basis. Equities research analysts anticipate that Cambrex Corp. will post $2.56 EPS for the current fiscal year.

In related news, CEO Steven M. Klosk sold 16,430 shares of the stock in a transaction on Thursday, May 5th. The stock was sold at an average price of $49.13, for a total transaction of $807,205.90. Following the sale, the chief executive officer now owns 136,828 shares of the company’s stock, valued at $6,722,359.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William B. Korb sold 3,420 shares of the stock in a transaction on Monday, July 11th. The shares were sold at an average price of $55.00, for a total value of $188,100.00. Following the sale, the director now directly owns 23,982 shares in the company, valued at approximately $1,319,010. The disclosure for this sale can be found here.

Several hedge funds recently bought and sold shares of CBM. Dimensional Fund Advisors LP raised its stake in Cambrex Corp. by 3.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,589,449 shares of the company’s stock worth $74,848,000 after buying an additional 47,279 shares during the last quarter. Principal Financial Group Inc. raised its stake in Cambrex Corp. by 2.3% in the fourth quarter. Principal Financial Group Inc. now owns 681,184 shares of the company’s stock worth $32,077,000 after buying an additional 15,623 shares during the last quarter. Century Capital Management LLC raised its stake in Cambrex Corp. by 13.5% in the fourth quarter. Century Capital Management LLC now owns 353,591 shares of the company’s stock worth $16,651,000 after buying an additional 42,189 shares during the last quarter. Morgan Stanley raised its stake in Cambrex Corp. by 27.9% in the fourth quarter. Morgan Stanley now owns 323,861 shares of the company’s stock worth $15,250,000 after buying an additional 70,585 shares during the last quarter. Finally, California Public Employees Retirement System raised its stake in Cambrex Corp. by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 162,700 shares of the company’s stock worth $7,662,000 after buying an additional 800 shares during the last quarter.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.